Treadwell Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Treadwell Therapeutics's estimated annual revenue is currently $4.3M per year.
- Treadwell Therapeutics's estimated revenue per employee is $77,500
- Treadwell Therapeutics's total funding is $118M.
Employee Data
- Treadwell Therapeutics has 56 Employees.
- Treadwell Therapeutics grew their employee count by -8% last year.
Treadwell Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Chairman & Co-CEO | Reveal Email/Phone |
2 | Founder, Chief Scientific Officer | Reveal Email/Phone |
3 | Sr VP, Development Operations | Reveal Email/Phone |
4 | VP CMC | Reveal Email/Phone |
5 | Director Information Technology | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Co-Founder and Chief Scientific Officer | Reveal Email/Phone |
9 | Clinical Project Manager | Reveal Email/Phone |
10 | Executive Chairman | Reveal Email/Phone |
Treadwell Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Treadwell Therapeutics?
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/
keywords:N/A
$118M
Total Funding
56
Number of Employees
$4.3M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Treadwell Therapeutics News
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia...
NEW YORK and HONG KONG, April 19, 2022 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company...
Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.2M | 56 | 22% | N/A |
#2 | $11.7M | 56 | 8% | N/A |
#3 | $7.8M | 56 | -11% | $108.8M |
#4 | $11.7M | 56 | 10% | N/A |
#5 | $8.4M | 56 | -8% | N/A |